PTPN2 (protein tyrosine phosphatase non-receptor type 2, also known as TC-PTP) is a cytosolic tyrosine phosphatase that functions as a negative regulator of a variety of tyrosine kinases and other signaling proteins 1-3 . In agreement with its role in the regulation of the immune system, PTPN2 was identified as a susceptibility locus for autoimmune diseases 4,5 . In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL). Deletion of PTPN2 was specifically found in T-ALLs with aberrant expression of the TLX1 transcription factor oncogene 6 , including four cases also expressing the NUP214-ABL1 tyrosine kinase 7 . Knockdown of PTPN2 increased the proliferation and cytokine sensitivity of T-ALL cells. In addition, PTPN2 was identified as a negative regulator of NUP214-ABL1 kinase activity. Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment.
PTPN2 (protein tyrosine phosphatase non-receptor type 2, also known as TC-PTP) is a cytosolic tyrosine phosphatase that functions as a negative regulator of a variety of tyrosine kinases and other signaling proteins [1] [2] [3] . In agreement with its role in the regulation of the immune system, PTPN2 was identified as a susceptibility locus for autoimmune diseases 4, 5 . In this work, we describe the identification of focal deletions of PTPN2 in human T-cell acute lymphoblastic leukemia (T-ALL). Deletion of PTPN2 was specifically found in T-ALLs with aberrant expression of the TLX1 transcription factor oncogene 6 , including four cases also expressing the NUP214-ABL1 tyrosine kinase 7 . Knockdown of PTPN2 increased the proliferation and cytokine sensitivity of T-ALL cells. In addition, PTPN2 was identified as a negative regulator of NUP214-ABL1 kinase activity. Our study provides genetic and functional evidence for a tumor suppressor role of PTPN2 and suggests that expression of PTPN2 may modulate response to treatment.
T-ALL is characterized by leukemic transformation of thymocytes caused by cooperative events altering proliferation, survival, cell cycle and differentiation of T cells 8, 9 . Despite considerable improvements in our understanding of the molecular genetics of T-ALL, the mechanisms that lead to the abnormal proliferation and/or survival of T lymphoblasts remain largely unknown 10 . To identify oncogenes or tumor suppressor genes involved in the development of T-ALL, we carried out microarray comparative genomic hybridization (array CGH) analysis using high-density oligonucleotide arrays 11 . In one individual, we detected an acquired homozygous microdeletion at chromosome 18p11 ( Fig. 1a and Supplementary Fig. 1 ). Fluorescence in situ hybridization (FISH) confirmed the presence of a homozygous deletion of PTPN2 in 90% of the bone marrow cells (Fig. 1b) . Quantitative PCR on genomic DNA isolated from diagnosis, remission and relapse confirmed that the deletion was acquired at diagnosis and was again present at relapse (Fig. 1c) .
PTPN2 is highly expressed in thymocytes 12 . To identify additional cases with deletion of PTPN2, we analyzed the gene expression profiles from 90 individuals with T-ALL (cases) 13 , which identified five individuals with low PTPN2 expression (Fig. 1d) . Analysis of genomic DNA confirmed the presence of acquired homozygous deletions restricted to the PTPN2 locus specifically in the five cases with low expression (Fig. 1a and Supplementary Fig. 2) . Notably, array CGH profiles indicated that in all cases with PTPN2 deletion, the breakpoints were highly similar. The deletion breakpoints were subsequently mapped within two Alu repeat regions flanking PTPN2 (Supplementary Fig. 3 ). SNP analysis excluded the presence of uniparental disomy at chromosome 18, providing evidence that deletion of the two different PTPN2 alleles occurred as two independent events.
We next screened an additional set of T-ALL cases (n = 106) for copy number alterations (n = 97), expression (n = 9) or mutations (n = 70) of PTPN2. Using this strategy, we identified two additional individuals with biallelic deletion and five individuals with monoallelic deletion of PTPN2 (Fig. 1a and Supplementary Fig. 4 ). Individuals with biallelic or monoallelic deletion of PTPN2 showed appreciably lower mRNA expression as compared with individuals with normal PTPN2 copy number ( Fig. 1e and Supplementary  Fig. 5 ). One individual with monoallelic deletion of PTPN2 harbored a nonsense mutation in the residual PTPN2 allele (Table 1) , but DNA methylation was not detected as a mechanism to silence PTPN2 gene expression in T-ALL (Supplementary Fig. 6 ). Deletion of PTPN2 was not detected in individuals with T-ALL who had normal PTPN2 expression or in individuals with acute myelogenous leukemia (n = 60, data not shown), or in published SNP array profiles from individuals with B-cell acute lymphoblastic leukemia 14 . Notably, all individuals with homozygous deletion of PTPN2 belonged to the TLX1-positive (n = 12) or TLX3-positive (n = 1) T-ALL subgroup (Fig. 1d , Table 1 and Supplementary Table 1) . TLX1-positive cells accumulate at the CD4 + CD8 + CD3 −/low differentiation stage 6 , where PTPN2 expression is high (Supplementary Fig. 7 ). This observation Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia suggests that CD4 + CD8 + CD3 −/low thymocytes may be most sensitive to loss of PTPN2 function. Our data show that inactivation of PTPN2 occurs in approximately 6% of individuals with T-ALL, associated with intermediate age (range 4-49 years, median 24 years) and the TLX1-positive subgroup (12 of 36 TLX1-positive individuals, 33%). Deletion of the entire PTPN2 gene is the most common inactivation mechanism.
PTPN2 was described as a phosphatase for both JAKs and STATs 15-17 , which are important signaling proteins downstream of cytokine receptors. To determine the effect of loss of PTPN2 on cytokine receptors implicated in T-cell development, we knocked down the expression of PTPN2 in human T-ALL cell lines and primary mouse T-ALL cells and measured the effect on receptor signaling for the cytokines IFN-γ, IL-2 and IL-7 18 . JURKAT cells were electroporated with PTPN2-targeting small interfering RNA (siRNA) or nontargeting siRNA and stimulated with IFN-γ for various time periods. Knockdown of PTPN2 resulted in a significant increase of both the strength and the time of JAK1 and STAT1 phosphorylation in this cell line (Fig. 2a) . HPB-ALL cells, another human T-ALL cell line, showed expression of the IL-7 receptor and were responsive to exogenous stimulation with IL-7. Knockdown of PTPN2 in these cells resulted in a clear increase of JAK1 and STAT5 phosphorylation in response to IL-7 stimulation (Fig. 2b) . 
l e t t e r s l e t t e r s
These data were further extended using ex vivo cultures of mouse primary T-cell leukemia cells, isolated from a spontaneous mouse T-cell leukemia (CD4 + CD8 + ), and expanded ex vivo in the presence of IL-2 and IL-7. Analysis of the response of these cells to IL-2 and IL-7 by monitoring amounts of phospho-JAK1 and phospho-STAT5
showed that knockdown of Ptpn2 caused an increased JAK/STAT signaling downstream of the IL-2 and IL-7 receptors (Fig. 3a,b) . In addition, for IFN-γ, a similar effect as observed in JURKAT cells was observed in the mouse T-cell leukemia cells (Fig. 3c) . To test whether the augmentation in cytokine responsiveness also provided l e t t e r s a proliferative advantage to these mouse T cells, we deprived cells of cytokines for 24 h and followed their proliferation after restimulation with either a low concentration of IL-7 alone or a combination of IL-2 and IL-7. Knockdown of Ptpn2 caused a significant increase in the proliferation as compared with control cells (Fig. 3d) . Taken together, the data obtained in human and mouse T-cell leukemias indicate that loss of PTPN2 sensitizes T-ALL cells to cytokine stimulation resulting in enhanced activation of cytokine receptor pathways, which may support T-ALL development and proliferation under limiting cytokine concentrations in vivo. In addition to a general effect on cytokine receptor signaling, our genetic data indicated a possible link between PTPN2 deletion and expression of the NUP214-ABL1 tyrosine kinase. Among nine NUP214-ABL1-positive T-ALLs analyzed in the described study, we have identified four NUP214-ABL1-positive individuals with a concomitant deletion of PTPN2. Two individuals (individuals 2 and 5) featured biallelicloss and two individuals (individuals 9 and 20) featured monoallelic loss of PTPN2 ( Table 1) . The presence of NUP214-ABL1 was initially detected by array CGH for all four individuals and later confirmed by FISH analysis for individuals 5, 9 and 20 (data not shown). In the case of individual 5, an extrachromosomal (episomal) amplification of ABL1 was detected in more than 80% of the bone marrow cells using the LSI BCR-ABL1 translocation probe (Abbott). For individual 20, both FISH and array CGH data confirmed a local duplication of NUP214-ABL1. In conclusion, deletions of both PTPN2 and NUP214-ABL1 were present in most cells and thus also occurred together within the same cells.
To determine whether PTPN2 directly modulates NUP214-ABL1 signaling, we applied a retroviral system that allowed us to induce stable overexpression of either wild-type PTPN2 or a catalytic inactive mutant (PTPN2-D182A) in ALL-SIL cells 19 . ALL-SIL is a cell line derived from a young adult individual with T-ALL expressing the NUP214-ABL1 fusion that is sensitive to the ABL1 kinase inhibitor imatinib 7 . Overexpression of wild-type PTPN2 in these cells resulted in a clear dephosphorylation of the NUP214-ABL1 protein, but this was not observed in cells expressing the catalytic inactive mutant (Fig. 4a) . The PTPN2-D182A mutant 
l e t t e r s
is also known to form a complex with physiological substrates that is stable enough to allow purification upon interaction 20, 21 .
Immune precipitation of the PTPN2-D182A from ALL-SIL cells resulted in coprecipitation of the NUP214-ABL1 protein, demonstrating a direct interaction between the tyrosine kinase and the phosphatase (Fig. 4a) . Finally, downregulation of PTPN2 in ALL-SIL cells resulted in a significant increase in proliferation of the cells under normal culture conditions (Fig. 4b) , which was in part attributed to increased signaling of NUP214-ABL1 through downstream proteins STAT5 and STAT3 (Fig. 4c) . In addition, other signaling proteins such as LCK, JAK3 and ERK1/2 were also found to be constitutively active in ALL-SIL cells and more activated upon PTPN2 knockdown and are therefore likely to contribute to the observed growth advantage (Fig. 4c,d) .
A similar relationship between NUP214-ABL1 and Ptpn2 was demonstrated in the IL-3-dependent pro-B cell line Ba/F3. We have previously shown that NUP214-ABL1 can transform Ba/F3 to IL-3-independent proliferation, but its oncogenic activity is less potent than the BCR-ABL1 kinase 22 . Short hairpin RNA (shRNA)-mediated downregulation of Ptpn2 expression made Ba/F3 cells more sensitive to NUP214-ABL1 transformation (Fig. 4e) . NUP214-ABL1 showed stronger autophosphorylation when expressed in Ba/F3 cells with decreased Ptpn2 expression, and vice versa, induced overexpression of wild-type PTPN2 decreased NUP214-ABL1 phosphorylation and downstream signaling (Fig. 4f,g ).
Next, we tested the effect of PTPN2 knockdown on the survival and proliferation of ALL-SIL cells upon treatment with the ABL1 kinase inhibitor imatinib. Downregulation of PTPN2 expression resulted in prolonged survival of ALL-SIL cells after imatinib treatment as compared with cells electroporated with a nontargeting siRNA (Fig. 5a) . The proliferation of the cells was inhibited by imatinib, but with a shift of the cellular IC 50 value from 73 to 126 nM (Fig. 5b) . These data indicate that loss of PTPN2 affects response to treatment, which is likely to be caused by the direct effect on NUP214-ABL1 activation and its downstream signaling, as observed by a higher activation state of its important downstream mediator STAT5 (Fig. 5c) . This is further supported by the enhanced phosphorylation of additional protein kinases such as LCK and ERK1/2, which persisted upon inhibitor treatment (Fig. 4c) . A similar effect was observed in HSB-2, a cell line derived from a childhood T-ALL that is dependent on LCK for its proliferation and survival 23 . Our results indicate a direct modulating effect of PTPN2 on LCK activation (Supplementary Fig. 8) .
Recently, mutational analysis of JAK1 resulted in the identification of activating point mutations in 10% of individuals with T-ALL 24 , directly implicating deregulated JAK1 signaling in the pathogenesis of leukemia. In this study we identify inactivation of PTPN2 in T-ALL cells as another mechanism that results in increased JAK/STAT signaling downstream of cytokine receptors. PTPN2 is an important negative regulator of a variety of tyrosine kinases as well as other signaling proteins, which indicates that its loss in T cells may affect a diverse set of signaling proteins thereby sensitizing T cells to growth factors and increasing the effects of oncogenic kinases such as NUP214-ABL1. Our data identify the NUP214-ABL1 oncogene as a new substrate of PTPN2 and show a correlation between activation status of the NUP214-ABL1 pathway, treatment response to kinase inhibitor imatinib and PTPN2 expression. This study adds further complexity to the genetics of T-ALL and shows that, in addition to tyrosine kinase activation, also inactivation of tyrosine phosphatases may provide a proliferation and survival advantage to these leukemias. Mutation and expression analysis of PTPN2 in various tumors is warranted.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
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Leukemia samples. T-ALL samples (n = 196) were collected at various institutions; expression patterns of some of these samples were described previously 13, 25 . All samples were obtained according to the guidelines of the local ethics committees. Diagnosis of T-ALL was based on morphology, cytochemistry and immunophenotyping according to the World Health Organization and European Group for the Immunological Characterization of Leukemias criteria 26, 27 .
Murine T cells. Primary mouse CD4 + CD8 + leukemic T cells were isolated from a mouse (Balb/c) suffering from an irradiation-induced T-ALL-like disease. Cells were expanded in RPMI-1640 medium supplemented with 20% FCS, IL-2 (5 ng/ml) and IL-7 (10 ng/ml) (Peprotech). The Ptpn2 locus was not affected in these cells; Notch1 was activated.
Array technology. Array CGH was carried out using the Agilent 244K platform (Agilent Technologies) or SNP array 6.0 (Affymetrix).
Cytogenetics and FISH analysis. Cytogenetic and FISH analyses were carried out following standard protocols 7, 28 . Fosmid probes covering regions within (G248P8043H2) or outside (G248P84981C11) the PTPN2 gene locus were designed based on UCSC Genome Browser and purchased from CHORI BACPAC Resources. Whole-chromosome painting probes for chromosome 18 (XCP18) were obtained from MetaSystems. LSI BCR-ABL ES (Abbott Molecular International) was used to identify ABL1 amplification.
Quantitative PCR. Fast SYBR Green Master Mix (Applied Biosystems) was used for performance of quantitative real-time PCR with the LightCycler 480 RealTime PCR System (Roche Diagnostics). CDH2 and RNMT were used as controls. Data were analyzed with the LC480 software (Roche Diagnostics) before applying the comparative ddCT method (Bulletin 2; Applied Biosystems) 11 . Primer sequences are provided in Supplementary Table 2. Sequence analysis of PTPN2. Genomic DNA was isolated from bone marrow or blood samples using the Wizard Genomic DNA Purification Kit (Promega). PCR reactions were carried out with Phusion Hot Start High-Fidelity DNA Polymerase (Finnzyme). GC-rich exon 1 was amplified using expand long template PCR system (Roche Diagnostics), and reactions were supplemented with betaine (Sigma) for improvement. All sequencing reactions were carried out on a 3130xl Genetic Analyzer (Applied Biosystems). mRNA expression analysis. TRIzol LS Reagent (Invitrogen) was used for total RNA extraction. cDNA synthesis and subsequent mRNA expression analysis of PTPN2 by real-time quantitative PCR was carried out as described previously 29 . HPRT was used as a reference gene for normalization.
Analysis of DNA methylation. Primer pairs were designed (Methyl Primer Express v 1.0 software) to bind sequences lacking any CpG islands. If CpG sites were unavoidable, degenerated bases were used. Genomic DNA was subjected to bisulfate treatment using the EZ DNA Methylation Kit (Zymo) followed by PCR amplification using AmpliTaq Gold 360 Polymerase (Applied Biosystems) or JumpStart REDTaq DNA polymerase (Sigma Aldrich). PCR products were directly sequenced. Nucleotide sequences in electropherograms were analyzed for cytosine or thymidine calls located in CpGs. An unmethylated control sample was included to assure complete bisulfate conversion.
Protein blotting and immunoprecipitation. Cells were lysed in lysis buffer (Cell Signaling) with complete protease inhibitor (Roche) and 1 mM NaVO 4 . For immunoprecipitation of proteins, precleared lysates were incubated overnight with Dynabeads protein G (Invitrogen) coupled to respective antibody. Equipment and settings. The LAS-3000 Imaging System (Fujifilm Global) was used for protein blot analysis. Quantification of protein blot data was carried out using Image J software.
Vectors and mutagenesis. PTPN2 was amplified from human cells using primers described previously 21 and cloned into the retroviral vector pMSCVpuro (Clontech) or the inducible pRetroX-PTuner system (Clontech). For knockdown of Ptpn2 in mouse cells, shRNA sequences targeting Ptpn2 or Alk (control) were cloned into pMSCV-GFP containing a mir30 flanking cassette (further referred to as GFP-miR30). shRNA sequences are listed in Supplementary Table 3 . For expression of NUP214-ABL1 22 and simultaneous knockdown of Ptpn2 in Ba/F3 cells, NUP214-ABL1 was recloned into a second multiple cloning site of the GFP-CmiR30 vector. PTPN2 trapping D182A mutant of the 45 kD form (PTPN2-D182A) 30, 31 was constructed. Wild-type PTPN2 (PTPN2-WT), PTPN2-D182A or GFP (negative control) were cloned into pRetroX-PTuner (Clontech). In this vector, the PTPN2 open reading frame was fused to a 12-kDa destabilizing domain. Addition of a stabilizing ligand (Shield1) resulted in stabilization and accumulation of the destabilizing domain-tagged protein. Protein expression was induced for 24 h (Shield1 concentration: 500 nM).
Cell culture, virus production, retroviral transduction. HEK293T and Ba/F3 cells were cultured, transfected and transduced as described previously 28 . For transformation assays, IL-3 was removed and cells were seeded out at 1 × 10 5 cells/ml. Cell number and viability were analyzed using Vi-cell XR cell viability analyzer (Beckman Coulter). Primary mouse leukemia T-ALL, ALL-SIL and HSB-2 cells were transduced using the spin infection method. Centrifugation of 200 μl of concentrated viral supernatant and 0.5 × 10 6 cells/ml medium containing 8 μg/ml polybrene was carried out for 90 min at 1,300 × g. At 48 h after transduction, human cell lines were selected with puromycin (1 μg/ml) for a period of 6 d.
Electroporation conditions and siRNA knockdown. Cells (2 × 10 6 ) from T-ALL cell lines were washed, resuspended in a total volume of 400 μl serumfree medium and transferred to a 4-mm cuvette (Biorad). Electroporation conditions were as follows: HPB-ALL, 500 μF/350 V; ALL-SIL, 1000 μF/275 V; JURKAT, 950 μF/300 V; HSB-2, 1000 μF/300 V. Electroporated cells were transferred to 12-well plates containing 2 ml prewarmed medium supplemented with 40% FBS for recovery. Effective siRNA delivery was assessed 4 h after electroporation using a fluorescent-labeled siRNA (BLOCK-iT, Invitrogen). siRNA duplexes were used at a final concentration of 200 nM. Cells were electroporated twice in 24 h (PTPN2 siRNA) using a GenePulser XCell electroporation system (Bio-Rad). Predesigned siRNA oligonucleotides were purchased from the DsRNA sequence library from Integrated DNA Technologies (IDT). Custom-designed duplexes targeting PTPN2 were obtained from Qiagen. Scrambled siRNA was used as negative control (IDT). siRNA sequences are listed in Supplementary Table 4. Signaling experiments. All signaling experiments were carried out at time point of optimal siRNA knockdown. For pathway analysis upon inhibitor exposure, ALL-SIL and HSB-2 cells were incubated with imatinib or PP2 (both 1 μM) for 90 min. In the case of cytokine signaling experiments, human T-ALL cells were serum-depleted for 4 h and primary leukemic mouse T cells were cytokine-depleted for 24 h before stimulation with respective cytokines.
Proliferation and drug inhibitor assays. Cells were seeded in triplicate at a cell density of 3 × 10 5 cells/ml (24-well plates) 24 h after the second electroporation, and either treatment was initiated for inhibitor experiments or cells were left untreated for proliferation assays. Primary leukemic mouse T cells were deprived of cytokines for 24 h before restimulation. Proliferation was assayed 24 and 48 h after addition of either a low concentration of
